Government widens probes of antipsychotic Risperdal

Johnson & Johnson has acknowledged that government probes into the sales and marketing of its antipsychotic drug Risperdal have been expanding. Risperdal was J&J's biggest seller last year, bringing in $3.55 billion. Investigators have been demanding internal corporate documents, including records of payments to doctors.

- read this Wall Street Journal report (sub. req.)

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.